Adverse reactions were manageable with EPKINLY1
Majority of adverse reactions were mild to moderate (grade 1 or 2)1
- Serious adverse reactions occurred in 54% of patients (reactions occurring ≥2%: CRS, infections, pleural effusion, febrile neutropenia, fever, and ICANS)1
- Fatal adverse reactions occurred in 3.8% of patients (1.3% COVID-19, 0.6% hepatotoxicity, 0.6% ICANS, 0.6% myocardial infarction, 0.6% pulmonary embolism)1
- Most adverse reactions occurred early in treatment (C1-3), and incidence declined after 12 weeks2
*Adverse reactions were graded based on CTCAE Version 5.0.
†Only grade 3 adverse reactions occurred.
‡CRS was graded using ASTCT consensus criteria (Lee et al, 2019).
§Term includes other related terms. See full Prescribing Information.
- Serious adverse reactions occurred in 54% of patients (reactions occurring ≥2%: CRS, infections, pleural effusion, febrile neutropenia, fever, and ICANS)1
- Fatal adverse reactions occurred in 3.8% of patients (1.3% COVID-19, 0.6% hepatotoxicity, 0.6% ICANS, 0.6% myocardial infarction, 0.6% pulmonary embolism)1
- Most adverse reactions occurred early in treatment (C1-3), and incidence declined after 12 weeks2
Low discontinuation rate (3.8%) due to adverse reactions1
- Adverse reactions that led to discontinuation included COVID-19, CRS, ICANS, pleural effusion, and fatigue1
- Dosage interruptions due to an adverse reaction occurred in 34% of patients (reactions occurring ≥3%: CRS, neutropenia, sepsis, and thrombocytopenia)1
ASTCT=American Society for Transplantation and Cellular Therapy; C1-3=cycles 1-3; COVID-19=coronavirus disease of 2019; CRS=cytokine release syndrome; CTCAE=Common Terminology Criteria for Adverse Events; ICANS=immune effector cell–associated neurotoxicity syndrome; NHL=non-Hodgkin lymphoma.
